Case Study

Strategic Brand Planning: Winning by Resource Optimization

Our client was a global biopharmaceutical company with a market-leading brand more than 20 years’ old. It came under intense pricing pressure due to generic entries from companies known to play primarily on price. The company faced issues in identifying key investment areas to help maintain the brand’s market leader position. Prescient was engaged to reevaluate the client’s business model through a series of projects designed to help the client

Net Present Value: Assessing Opportunities for Indication Expansion

Our client, a European specialty pharmaceutical company, was considering an expansion of indications within its target therapeutic group via licensing and acquiring products that were in clinical development, soon-to-be-launched or already marketed. The client engaged Prescient to prepare a comprehensive commercial valuation of a late-stage licensing opportunity to support the assessment of a go/no-go decision and subsequent submission of a non-binding offer, resulting in full due diligence or potential negotiation and closing of a deal or partnership.

Stakeholder Engagement Strategies: Providing a Deeper Understanding of Potential Customers

Our client, a global pharmaceutical company, was in the process of strengthening the vision for its future product portfolio. The marketing team needed to identify potential high-prescribing customers to develop a marketing campaign that would support its strategy for optimally co-positioning future therapies. There were several unknowns about the potential license for our client’s product, …

Stakeholder Engagement Strategies: Providing a Deeper Understanding of Potential Customers Read More »

Late Life Cycle Management Strategies: Developing Long-Range Plans to Retain and Grow Market Share

Our global pharmaceutical client’s mature product was two years away from patent expiry in its key regulated markets and faced imminent generic competition. The company engaged Prescient to understand the likely impact of changes in the competitive landscape, market dynamics and stakeholder behavior. The engagement was expected to prepare the client for generic entry by: …

Late Life Cycle Management Strategies: Developing Long-Range Plans to Retain and Grow Market Share Read More »

Phase III Decision Support: Evidence-Based and Objective Risk Assessment

Our client, a global pharmaceutical company, sought to decide whether to progress two internal assets into Phase III development based on the Phase II data. The client engaged Prescient to: 1) perform an in-depth assessment of the Phase II data and comparative analyses with in-line and pipeline competitor products; 2) evaluate the potential changes in …

Phase III Decision Support: Evidence-Based and Objective Risk Assessment Read More »

Peri-Launch Support: Defining the Market and Changing Current Practice

Our client, a global pharmaceutical company, planned to launch a new product about six months ahead of a direct competitor in an indication with no effective treatment options. As physicians had many options for acute treatment for this chronic disease, the client engaged Prescient to define the market and help change the current practice. Shaping …

Peri-Launch Support: Defining the Market and Changing Current Practice Read More »

Market Access Strategy Development: Providing a Clear, Strategic Direction

Our client, a global pharmaceutical company, wanted to devise a global strategy to proactively address threats from the launch of biosimilars across various geographies. The client engaged Prescient to determine which of the four major stakeholders (payer, physician, pharmacist or patient) influenced the overall uptake of biosimilars across different market archetypes. Shaping Decisions | Driving …

Market Access Strategy Development: Providing a Clear, Strategic Direction Read More »

Market Opportunity Mapping: Identifying Opportunities for a First-in-Class Product in a Crowded Space

Our client, a global pharmaceutical company, needed to identify opportunities in the EU5 countries for a first-in-class injectable product entering a crowded generic market. The client’s product was expected to obtain marketing authorization on the back of positive Phase III trials using surrogate endpoints and not hard clinical endpoints. Shaping Decisions | Driving Value Prescient …

Market Opportunity Mapping: Identifying Opportunities for a First-in-Class Product in a Crowded Space Read More »

Scroll to Top